keyword
MENU ▼
Read by QxMD icon Read
search

lmwh cancer

keyword
https://www.readbyqxmd.com/read/29455568/effectiveness-and-safety-of-lmwh-treatment-in-patients-with-cancer-diagnosed-with-non-high-risk-venous-thromboembolism-turkish-observational-study-trebeca
#1
Ersin Ozaslan, Metin Ozkan, Irfan Cicin, Mustafa Benekli, Murat Kocer, Mukremin Uysal, Berna Oksuzoglu, Abdurrahman Isikdogan, Erdem Cubukcu, Emin T Elkiran, Faysal Dane, Mehmet Aliustaoglu, Alper Sevinc, Aziz Karaoglu, Arife Ulas, Gamze Gokoz-Dogu
We compared the efficacy and safety of low-molecular-weight heparins (LMWHs) in patients with cancer who are at low risk of venous thromboembolism (VTE). Patients were treated by medical oncologists in Turkey at 15 sites, where they were enrolled and followed up for a period of 12 months. Due to the study design, there was no specific treatment protocol for LMWH. Primary end points were efficacy and the time to change in VTE status. Of the included 250 patients, 239 (95.6%), 176 (70.4%), 130 (52.0%), and 91 (36...
January 1, 2018: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/29417289/thromboprophylaxis-and-the-route-of-administration-of-chemotherapy-in-testicular-cancer-patients-in-german-speaking-countries
#2
Tim Nestler, Johannes Huber, Adrienne M Laury, Hendrik Isbarn, Axel Heidenreich, Hans U Schmelz, Christian G Ruf
PURPOSE: Due to the excellent cure rates for testicular cancer (TC), focus has shifted towards decreasing therapy-related morbidities. Thrombosis is a frequent complication of cisplatin chemotherapy. Furthermore, the optimal route of administration for chemotherapy is still under debate. The purpose of this study was to assess the patterns of care concerning dosing and duration of thromboprophylaxis currently utilized in TC patients in German-speaking countries as well as the route of chemotherapy administration...
February 7, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29409771/development-of-low-molecular-weight-heparin-based-nanoparticles-for-metastatic-breast-cancer-therapy
#3
Haifeng Sun, Dinglingge Cao, Hao Wu, Huan Liu, Xue Ke, Tianyuan Ci
Tumor metastasis is the primary obstacle in cancer treatment and is always the leading cause of human death. And heparin and its derivatives are potential anti-metastatic agents with good biocompatibility. In this work, low molecular weight heparin (LMWH) based LMWH-Cholesterol (LHC) conjugates were prepared for intravenous delivery of doxorubicin (DOX). The DOX/LHC nanoparticles (DOX/LHC NPs) exhibited a spherical shape with a mean diameter of 135.5 ± 2.2 nm and had a longer circulation time than that of DOX...
January 30, 2018: International Journal of Biological Macromolecules
https://www.readbyqxmd.com/read/29407633/the-lectin-pathway-and-coagulation-in-lung-cancer-patients-undergoing-lobectomy-a-randomised-controlled-trial
#4
Julie Brogaard Larsen, Anne Troldborg, Thomas Decker Christensen, Christine Lodberg Hvas, Steffen Thiel, Anne-Mette Hvas
BACKGROUND: Lectin pathway proteases activate coagulation and may theoretically play a role in the increased thrombosis risk in cancer, which is especially high during surgery. AIMS: To investigate lectin pathway proteins during lung cancer surgery, the influence of low molecular weight heparin (LMWH) on lectin pathway proteins, and correlations between lectin pathway proteins and coagulation. METHODS: Fifty lung cancer patients undergoing video-assisted thoracoscopic surgery lobectomy were randomised to LMWH, n = 26, or no anticoagulant (control), n = 24...
January 30, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29397103/caprini-risk-model-decreases-venous-thromboembolism-rates-in-thoracic-surgery-cancer-patients
#5
Helene M Sterbling, Amy K Rosen, Krista J Hachey, Niru S Vellanki, Philip D Hewes, Sowmya R Rao, Emma Pinjic, Hiran C Fernando, Virginia R Litle
BACKGROUND: Extended postoperative chemoprophylaxis is effective in reducing venous thromboembolism (VTE) among general surgical patients. We hypothesized that implementation of the Caprini risk assessment model (RAM) would reduce VTE rates among patients undergoing lung and esophageal cancer surgery. METHODS: The Caprini RAM, consisting of patient risk stratification and extended postoperative chemoprophylaxis with low molecular weight heparin, was implemented on the thoracic surgery service at Boston Medical Center in July 2014...
January 31, 2018: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/29396864/effectiveness-and-safety-of-anticoagulants-for-the-treatment-of-venous-thromboembolism-in-patients-with-cancer
#6
Michael Blake Streiff, Dejan Milentijevic, Keith McCrae, Daniel Yannicelli, Jonathan Fortier, Winnie W Nelson, François Laliberté, Concetta Crivera, Patrick Lefebvre, Jeff Schein, Alok A Khorana
Anticoagulation is used to treat venous thromboembolism (VTE) in cancer patients, but may be associated with an increased risk of bleeding. VTE recurrence and major bleeding were assessed in cancer patients treated for VTE with the most currently prescribed anticoagulants in clinical practice. Newly diagnosed cancer patients (first VTE 1/1/2013-05/31/2015) who initiated rivaroxaban, low-molecular-weight heparin (LMWH), or warfarin were identified from Humana claims data and observed until end of eligibility or end of data availability...
February 3, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29389673/low-molecular-weight-heparin-versus-rivaroxaban-in-the-treatment-of-venous-thromboembolism-in-gastrointestinal-malignancies
#7
Hannah K Choe, Maria T De Sancho, Sunnie S Kim, Tong Dai, Manish A Shah
: Due to their ease of use, the direct oral anticoagulants (DOACs) are an attractive treatment option for cancer-associated venous thromboembolism (VTE) and have been readily adopted by many clinicians. A recent published study comparing a DOAC (edoxaban) to the current standard-of-care low molecular weight heparin dalteparin for the treatment of cancer-associated thrombosis showed that edoxaban was noninferior to dalteparin for recurrent VTE, but the risk of major bleeding was higher. We present three patients with high-risk gastrointestinal malignancies complicated by cancer-associated VTE with progression of thrombosis while treated with the oral direct Xa inhibitor rivaroxaban...
January 31, 2018: Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis
https://www.readbyqxmd.com/read/29384941/concomitant-coronary-and-pulmonary-embolism-associated-with-patent-foramen-ovale-a-case-report
#8
Zhongxiu Chen, Chen Li, Yajiao Li, Hong Tang, Li Rao, Mian Wang
RATIONALE: The differential diagnosis of acute chest pain is very important, and can sometimes be challenging. Related diseases share a number of risk factors, and occasionally, 1 condition causes another disease to develop. PATIENT CONCERNS: We described a 59-year-old man who presented to emergency department complaining of chest pain. DIAGNOSES: He was suffered acute myocardial infarction (MI) and pulmonary embolism (PE) simultaneously. INTERVENTIONS: Dual antiplatelet therapy, statin, and low molecular weight heparin were administrated during his stay...
December 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29384885/recurrent-stroke-in-a-patient-of-lung-cancer-without-pulmonary-mass-a-case-report
#9
Lisha Wang, Yan Xu, Minghui Tuo, Lei Zhang, Hong Zhang, Jing Wang
RATIONALE: Repeated occurring stroke in short intervals with hypercoagulability is unusual so in such cases the conventional vascular risk factors might not be the causes of stroke. PATIENT CONCERNS: We have presented a case of 60-year-old male presenting with recurrent stroke due to thrombophilia. DIAGNOSES: Lung cancer was detected by superficial lymph nodes ultrasound and further pathological examination. INTERVENTIONS: The patient suffered a recurrent stroke and he had persistently high level of D-dimer which suggested the diagnosis of thrombophilia, thus, he was treated with low-molecular-weight heparin...
February 2018: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29376959/-clinical-experience-with-the-use-of-rivaroxaban-in-the-treatment-of-cancer-patients-with-venous-thrombosis
#10
P F Kravtsov, S E Katorkin, M A Melnicov
The urgency of the problem. The incidence of various thromboembolic complications in patients with oncopathology reaches 5-12%. When treating VTE in patients with oncology it is necessary to choose between two generally recognized alternatives. The recommended two-component scheme of the initiating phase of anticoagulant therapy with subsequent long-term admission of VKA is fraught with the development of clinically significant bleeding during the initial selection of the dose of warfarin and an increased risk of recurrence of VTE...
2018: Khirurgiia
https://www.readbyqxmd.com/read/29370290/incidence-of-venous-thromboembolism-in-korea-from-2009-to-2013
#11
Junshik Hong, Ju Hyun Lee, Ho-Young Yhim, Won-Il Choi, Soo-Mee Bang, Heeyoung Lee, Doyeun Oh
The incidence of venous thromboembolism (VTE) is lower in Asian populations than in Western populations. The objective of the present study was to evaluate the annual age- and sex-adjusted incidence (ASR) of VTE from 2009 to 2013 in South Korea. In addition, annual change in the pattern of VTE treatment during the study period was estimated because a new direct oral anticoagulant (DOAC) had become available and was covered by health insurance in Korea beginning in January 2013. VTE cases from 2009 to 2013 were retrospectively identified based on both diagnostic and medication codes of anticoagulants used for initial treatment using the Korean Health Insurance Review and Assessment Service (HIRA) databases...
2018: PloS One
https://www.readbyqxmd.com/read/29363105/anticoagulation-for-the-initial-treatment-of-venous-thromboembolism-in-people-with-cancer
#12
REVIEW
Maram B Hakoum, Lara A Kahale, Ibrahim G Tsolakian, Charbel F Matar, Victor Ed Yosuico, Irene Terrenato, Francesca Sperati, Maddalena Barba, Holger Schünemann, Elie A Akl
BACKGROUND: Compared with people without cancer, people with cancer who receive anticoagulant treatment for venous thromboembolism (VTE) are more likely to develop recurrent VTE. OBJECTIVES: To compare the efficacy and safety of three types of parenteral anticoagulants (i.e. fixed-dose low molecular weight heparin (LMWH), adjusted-dose unfractionated heparin (UFH), and fondaparinux) for the initial treatment of VTE in people with cancer. SEARCH METHODS: A comprehensive search included a major electronic search of the following databases: Cochrane Central Register of Controlled Trials (CENTRAL) (2018, Issue 1), MEDLINE (via Ovid) and Embase (via Ovid); handsearching of conference proceedings; checking of references of included studies; use of the 'related citation' feature in PubMed; and a search for ongoing studies...
January 24, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29361618/-management-of-venous-thromboembolism-in-cancer-patients
#13
Seiji Madoiwa
The clinical relevance of the association between venous thromboembolism(VTE)and cancer is well documented. VTE is one of the leading causes of death in cancer patients. It would be an advantage to have knowledge on predictive parameters for the development of thrombosis and to be able to select cancer patients individually according to their riskprofiles. An elevated platelet count is associated with an increased riskof VTE in cancer patients. The biomarkers including D-dimer have been identified and used to extend the existing riskstratification...
December 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29353682/predicting-the-risk-of-recurrent-venous-thromboembolism-in-patients-with-cancer-a-prospective-cohort-study
#14
Nick van Es, Martha Louzada, Marc Carrier, Vicky Tagalakis, Peter L Gross, Sudeep Shivakumar, Marc A Rodger, Philip S Wells
BACKGROUND: The risk of recurrent venous thromboembolism (VTE) in cancer patients despite anticoagulant therapy is high. Clinical factors and pro-coagulant markers may identify high-risk patients and guide decisions about intensifying anticoagulation therapy. AIMS: To evaluate whether serial measurements of pro-coagulant markers can identify patients at high risk of recurrent VTE. METHODS: In this multicenter, prospective cohort study, patients with active cancer and acute deep vein thrombosis or pulmonary embolism were enrolled...
January 9, 2018: Thrombosis Research
https://www.readbyqxmd.com/read/29353416/physicians-decision-about-long-term-thromboprophylaxis-in-cancer-outpatients-cat-axis-a-case-vignette-study-on-clinical-practice-in-france
#15
Florian Scotté, I Elalamy, D Mayeur, G Meyer
PURPOSE: Data on long-term venous thromboembolism prophylaxis in cancer outpatients remain scarce. In the absence of clear and consistent treatment guidelines, our objectives were to describe and better understand clinical practice and to identify factors influencing the use of thromboprophylaxis. METHODS: CAT AXIS was a multicentred cross-sectional study based on the completion of physician-profile questionnaires and the assessment of 10 e-mailed credible clinical scenarios of lung, colon and breast cancers by each of participants using the case vignette-validated method...
January 20, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29325825/-thromboembolic-disease-in-pediatric-oncology
#16
A Theron, C Biron-Andreani, S Haouy, L Saumet, M Saguintah, E Jeziorski, N Sirvent
The survival rate of children with cancer is now close to 80 %, as a result of continuous improvement in diagnostic and treatment procedures. Prevention and treatment of treatment-associated complications is now a major challenge. Thromboembolic venous disease, due to multifactorial pathogenesis, is a frequent complication (up to 40 % asymptomatic thrombosis in children with cancer), responsible for significant morbidity. Predominantly in children with acute lymphoblastic leukemia, lymphoma, or sarcoma, thromboembolic disease justifies primary prophylaxis in certain populations at risk, whether genetic or environmental...
January 8, 2018: Archives de Pédiatrie: Organe Officiel de la Sociéte Française de Pédiatrie
https://www.readbyqxmd.com/read/29325495/management-of-cancer-associated-venous-thromboembolism-a-case-based-practical-approach
#17
Minna Voigtlaender, Florian Langer
In patients with solid tumours or haematological malignancies, venous thromboembolism (VTE) is a leading cause of death and significantly contributes to morbidity and healthcare resource utilization. Current practice guidelines recommend long-term anticoagulation with low-molecular-weight heparin (LMWH) as the treatment of choice for cancer-associated VTE, based on clinical trial data showing an overall improved safety and efficacy profile of LMWH compared to vitamin K antagonists. However, several open questions remain, e...
January 12, 2018: VASA. Zeitschrift Für Gefässkrankheiten
https://www.readbyqxmd.com/read/29321061/enoxaparin-attenuates-doxorubicin-induced-cardiotoxicity-in-rats-via-interfering-with-oxidative-stress-inflammation-and-apoptosis
#18
Reem Ali Shaker, Samer Hassan Abboud, Hayder Chasib Assad, Najah Hadi
BACKGROUND: Doxorubicin (DOX) is commonly used in the treatment of many types of cancers but its cardiotoxicity is limiting its clinical use. Beyond its anticoagulant action, enoxaparin (ENX), a low molecular weight heparin, has been shown to exert multiple pharmacological actions including antioxidant, anti-inflammatory and antiapoptotic effects. Therefore, the current study aimed to assess if ENX could ameliorate cardiotoxicity induced by DOX. METHODS: Twenty-one adult male Wistar albino rats were randomly allocated into three groups (n = 7 each) of control, receiving 0...
January 10, 2018: BMC Pharmacology & Toxicology
https://www.readbyqxmd.com/read/29284351/recurrence-of-malignancy-associated-venous-thromboembolism-among-patients-treated-with-rivaroxaban-compared-to-enoxaparin
#19
Megan D Nicklaus, Shannon L Ludwig, Jacob K Kettle
Purpose Although low-molecular-weight heparin (LMWH) remains the standard of care, factor Xa inhibitors such as rivaroxaban may serve as an alternative treatment for venous thromboembolism (VTE) in patients with active malignancy. The purpose of the analysis was to evaluate outcomes of VTE management in cancer patients treated with rivaroxaban compared to enoxaparin. Methods This single-center retrospective analysis was conducted on patients with malignancy-associated VTE initiated on treatment with either rivaroxaban or enoxaparin...
January 1, 2017: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29274307/vitamin-k-antagonists-after-6-months-of-low-molecular-weight-heparin-in-cancer-patients-with-venous-thromboembolism
#20
Chatree Chai-Adisaksopha, Alfonso Iorio, Mark A Crowther, Javier de Miguel, Estuardo Salgado, Marija Zdraveska, Carmen Fernández-Capitán, José Antonio Nieto, Giovanni Barillari, Laurent Bertoletti, Manuel Monreal
BACKGROUND: Low-molecular-weight heparin (LMWH) is the treatment of choice in cancer patients with venous thromboembolism. However, data on continuing LMWH treatment beyond six months remain scanty. METHODS: We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) registry to compare the rate of venous thromboemblism recurrences and major bleeding appearing beyond the first 6 months of anticoagulant therapy in cancer patients with venous thromboemblism, according to therapy with LMWH or vitamin K antagonists (VKA)...
December 20, 2017: American Journal of Medicine
keyword
keyword
68448
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"